Oscar Siu Hong Chan1, Marcin Kowanetz2, Wai Tong Ng3, Hartmut Koeppen4, Lai Kwan Chan5, Rebecca Mei Wan Yeung6, Haiyan Wu7, Lukas Amler8, Christoph Mancao9. 1. Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Road, Chai Wan, Hong Kong. Electronic address: chansh2@ha.org.hk. 2. Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA. Electronic address: kowanetz.marcin@gene.com. 3. Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Road, Chai Wan, Hong Kong. Electronic address: ngwt1@ha.org.hk. 4. Biometrics, Roche (China) Holding Ltd., Beijing, China. Electronic address: koeppen.hartmut@gene.com. 5. Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Road, Chai Wan, Hong Kong. Electronic address: clk710@ha.org.hk. 6. Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Road, Chai Wan, Hong Kong. Electronic address: yeungmwr@ha.org.hk. 7. Biometrics, Roche (China) Holding Ltd., Beijing, China. Electronic address: haiyan.wu.hw1@roche.com. 8. Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA. Electronic address: amler.lukas@gene.com. 9. Oncology Biomarker Development, Genentech Inc., CH-4070 Basel, Switzerland. Electronic address: christoph.mancao@roche.com.
Abstract
OBJECTIVES: Locally recurrent or metastatic nasopharyngeal cancer (NPC) remains an important challenge, with more effective and durable therapeutic options needed. Cancer immunotherapy, and in particular therapies that target the PD-L1/PD-1 immune checkpoint pathway, may provide new options to treat NPC patients. This study evaluated PD-L1 and CD8 expression levels and the respective associations with clinical and histopathological characteristics of patients with NPC. MATERIALS AND METHODS: Diagnostic tumour biopsies were obtained before radical radiotherapy with or without chemotherapy from 161 patients with NPC. These biopsies were analysed for PD-L1 expression levels on tumour cells (TC) and tumour-infiltrating immune cells (IC), and for CD8 T-cell infiltration. Results were correlated with baseline characteristics and clinical outcomes with standard-of-care treatment regimens. Additionally, pre- and post-treatment-paired tumour samples were analysed (n=146). RESULTS: 75% of tumours expressed PD-L1 on IC and 24% on TC. Baseline clinical characteristics of stage, sex and age did not correlate with PD-L1 expression. Additionally, overall survival and progression-free survival of standard-of-care treatment did not correlate with baseline PD-L1 expression. CD8 levels did correlate with clinical outcomes; however, results were confounded by other baseline characteristics. After treatment, PD-L1 expression dropped a median of 1.5% on IC and a median of 2.75% on TC. Median CD8 expression dropped 1.9%. CONCLUSIONS: Majority of NPC biopsy samples demonstrated PD-L1 expression on ⩾1% of IC, with fewer expressing PD-L1 on TC. In contrast to previous smaller studies, no prognostic value was observed for PD-L1 expression levels in patients with NPC.
OBJECTIVES: Locally recurrent or metastatic nasopharyngeal cancer (NPC) remains an important challenge, with more effective and durable therapeutic options needed. Cancer immunotherapy, and in particular therapies that target the PD-L1/PD-1 immune checkpoint pathway, may provide new options to treat NPCpatients. This study evaluated PD-L1 and CD8 expression levels and the respective associations with clinical and histopathological characteristics of patients with NPC. MATERIALS AND METHODS: Diagnostic tumour biopsies were obtained before radical radiotherapy with or without chemotherapy from 161 patients with NPC. These biopsies were analysed for PD-L1 expression levels on tumour cells (TC) and tumour-infiltrating immune cells (IC), and for CD8 T-cell infiltration. Results were correlated with baseline characteristics and clinical outcomes with standard-of-care treatment regimens. Additionally, pre- and post-treatment-paired tumour samples were analysed (n=146). RESULTS: 75% of tumours expressed PD-L1 on IC and 24% on TC. Baseline clinical characteristics of stage, sex and age did not correlate with PD-L1 expression. Additionally, overall survival and progression-free survival of standard-of-care treatment did not correlate with baseline PD-L1 expression. CD8 levels did correlate with clinical outcomes; however, results were confounded by other baseline characteristics. After treatment, PD-L1 expression dropped a median of 1.5% on IC and a median of 2.75% on TC. Median CD8 expression dropped 1.9%. CONCLUSIONS: Majority of NPC biopsy samples demonstrated PD-L1 expression on ⩾1% of IC, with fewer expressing PD-L1 on TC. In contrast to previous smaller studies, no prognostic value was observed for PD-L1 expression levels in patients with NPC.
Authors: E Muraro; E Vaccher; C Furlan; E Fratta; G Fanetti; D A Fae'; D Martorelli; M Cangemi; J Polesel; F Navarria; C Gobitti; E Comaro; C Scaini; C Pratesi; S Zanussi; V Lupato; G Grando; V Giacomarra; S Sulfaro; L Barzan; R Dolcetti; A Steffan; V Canzonieri; G Franchin Journal: Pathol Oncol Res Date: 2020-06-21 Impact factor: 3.201
Authors: Brigette B Y Ma; Wan-Teck Lim; Boon-Cher Goh; Edwin P Hui; Kwok-Wai Lo; Adam Pettinger; Nathan R Foster; Jonathan W Riess; Mark Agulnik; Alex Y C Chang; Akhil Chopra; Julie A Kish; Christine H Chung; Douglas R Adkins; Kevin J Cullen; Barbara J Gitlitz; Dean W Lim; Ka-Fai To; K C Allen Chan; Y M Dennis Lo; Ann D King; Charles Erlichman; Jun Yin; Brian A Costello; Anthony T C Chan Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 50.717